10 Value Stocks in Ken Fisher’s Portfolio

8. Merck & Co., Inc. (NYSE:MRK)

Fisher Asset Management Equity Stake: $1.60 Billion

Forward P/E Ratio as of April 17: 8.49

Number of Hedge Holders: 91

Merck & Co., Inc. (NYSE:MRK) is a healthcare company that focuses on delivering innovative solutions through prescription medicines, vaccines, and animal health products. It also has a presence in Life Science and Electronics, equipment, and services sectors. While the stock has pulled back significantly, it remains a top-value stock in Ken Fisher’s portfolio as it is trading at a low price-to-earnings multiple of 8.49.

On April 8, Goldman Sachs reiterated a Buy rating on Merck & Co., Inc. (NYSE:MRK) even as it cut its price target to $103 from $129. The bullish stance stems from growing optimism that the company’s Animal Health division, which generated a record $6 billion in revenues in 2024, will remain a key growth driver

In addition, Merck & Co., Inc. (NYSE:MRK) has moved to reinvigorate its growth metrics with a $493 million licensing deal with Austria-based drug delivery technology maker Cyprumed on April 15. The deal paves the way for the company to unlock new growth opportunities around oral tablets. Merck obtains the opportunity to exclusively license the technology for additional specific targets in addition to nonexclusive worldwide rights to Cyprumed’s oral peptide delivery platform for an unspecified number of targets.